Paracetamol Al Comp.

Active Ingredient:: Paracetamol, Codeine Phosphate Hemihydrate
Origin:: EU

Paracetamol Al Comp. (Paracetamol, Codeine Phosphate Hemihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Paracetamol, the active ingredient in Paracetamol Al Comp., is an analgesic presented as a combination tablet for oral use. It treats mild to moderate pain and reduces fever in adults and children when used as directed.

GNH India supplies Paracetamol Al Comp. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aliud Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Paracetamol Al Comp. combines a non‑opioid analgesic with an opioid component to manage pain through central and peripheral pathways.

Acute musculoskeletal pain: provides relief of pain and improves mobility.
Post‑operative pain: helps control pain after surgical procedures.
Severe dental pain: reduces intense dental discomfort and facilitates dental treatment.
Cough‑related fever: lowers fever associated with respiratory infections.
Chronic lower back pain: assists in managing persistent lower‑back discomfort.

How It Works

Paracetamol works by inhibiting cyclooxygenase enzymes in the central nervous system, reducing prostaglandin synthesis and thereby lowering pain perception and fever. Codeine phosphate hemihydrate is a pro‑drug that is metabolised to morphine, which activates µ‑opioid receptors in the brain and spinal cord, producing analgesia and a mild cough‑suppression effect.

Side Effects

Paracetamol Al Comp. may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

Nausea: mild to moderate stomach upset.
Drowsiness: feeling of sleepiness or reduced alertness.
Constipation: difficulty passing stools.
Dizziness: light‑headed sensation.
Dry mouth: reduced salivation.
Sweating: increased perspiration.

Serious or Rare Side Effects

Respiratory depression: slowed breathing, especially at higher opioid doses.
Hepatotoxicity: liver injury from excessive paracetamol exposure.
Allergic reactions: rash, itching, or swelling.
Seizures: rare occurrence, often linked to overdose.
Severe hypotension: marked drop in blood pressure.
Dependence or withdrawal: signs of opioid dependence with prolonged use.

Precautions & Warnings

When using Paracetamol Al Comp., consider the following safety measures:

Liver function monitoring: assess hepatic health before and during therapy.
Opioid tolerance assessment: evaluate patient’s prior exposure to opioid analgesics.
Concomitant CNS depressants: avoid or limit use with other sedatives.
Pregnancy and lactation: use only if clearly needed and prescribed.
Alcohol consumption: limit intake to reduce liver risk.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Paracetamol Al Comp. can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

Benzodiazepines: combined CNS depression may be dangerous.
MAO inhibitors: risk of severe hypertension or serotonin syndrome.
Strong CYP2D6 inhibitors (e.g., fluoxetine): may increase codeine levels.

Moderate Interactions (Monitor Closely)

Anticoagulants (e.g., warfarin): may enhance bleeding risk.
Antihistamines: can increase drowsiness.
Alcohol: raises risk of liver toxicity.

Frequently Asked Questions

Paracetamol Al Comp. is a combination analgesic that contains paracetamol and codeine phosphate hemihydrate. It is prescribed to relieve moderate to severe pain and to reduce fever, commonly in conditions such as post‑operative pain, dental pain, musculoskeletal injuries and fever associated with respiratory infections.

Paracetamol reduces pain and fever by inhibiting central cyclooxygenase enzymes, which lowers prostaglandin production in the brain. This action decreases the perception of pain and helps reset the body’s temperature set‑point, providing antipyretic effects.

The appropriate dose of Paracetamol Al Comp. is determined by a qualified prescriber based on the patient’s age, weight, pain severity and overall health status. Healthcare professionals tailor the regimen to achieve effective pain control while minimizing risk.

Paracetamol Al Comp. should only be used in pregnancy or while breastfeeding if clearly indicated by a healthcare professional. Paracetamol alone is generally considered low‑risk, but the codeine component may pose risks to the fetus or infant, so a risk‑benefit assessment is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑opioid analgesics such as ibuprofen, Paracetamol Al Comp. adds an opioid (codeine) which provides stronger pain relief for moderate to severe pain. Unlike pure opioid products, the paracetamol component offers antipyretic benefits and may allow lower opioid dosing, reducing some opioid‑related risks.

Store Paracetamol Al Comp. at temperatures below 25 °C in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency and stability throughout its shelf life.

Paracetamol Al Comp. is supplied as oral tablets that should be swallowed whole with water. It is typically taken at regular intervals as prescribed, and food intake does not significantly affect its absorption.

The most serious risks include respiratory depression, especially in opioid‑naïve patients or when combined with other depressants, and liver injury from excessive paracetamol intake. Signs of severe adverse reactions require immediate medical attention.

Individuals with known hypersensitivity to paracetamol, codeine or any excipients, patients with severe hepatic impairment, those with significant respiratory conditions, and patients taking MAO inhibitors should avoid this medication unless a specialist advises otherwise.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 13 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.